S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
What To Do With Your Trades Today (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
What To Do With Your Trades Today (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
What To Do With Your Trades Today (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
What To Do With Your Trades Today (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
What To Do With Your Trades Today (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
What To Do With Your Trades Today (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What’s At Stake In April is Shocking (Ad)pixel
UK travelers face hours-long waits for ferries to France
'War of the states': EV, chip makers lavished with subsidies
What To Do With Your Trades Today (Ad)pixel
Gas prices increase in NJ, around nation amid higher demand
Lanterns and crescents: more retailers court Ramadan buyers
What To Do With Your Trades Today (Ad)pixel
Shipbuilder Austal executives accused of inflating earnings
No more room for vroom? Paris votes on banishing e-scooters
NASDAQ:DBVT

DBV Technologies - DBVT Stock Forecast, Price & News

$1.69
+0.03 (+1.81%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
$1.61
$1.72
50-Day Range
$1.28
$1.73
52-Week Range
$1.08
$3.43
Volume
9,264 shs
Average Volume
36,805 shs
Market Capitalization
$318.18 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.38

DBV Technologies MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
218.0% Upside
$5.38 Price Target
Short Interest
Healthy
0.95% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.00mentions of DBV Technologies in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.97) to ($0.91) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

860th out of 996 stocks

Biological Products, Except Diagnostic Industry

147th out of 165 stocks


DBVT stock logo

About DBV Technologies (NASDAQ:DBVT) Stock

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

DBVT Stock News Headlines

DBV Technologies (NASDAQ:DBVT) Now Covered by StockNews.com
What’s At Stake In April is Shocking
The Fed will be meeting on a topic that could change trading forever, and the decision could come as soon as the end of April. But by taking the smartest approach now, you can help shield your assets and work toward your trading goals. Time, as always, is of the essence. Click on this link to see what you need to do right away. pixel
DBV Technologies Update
Bear market expert makes new prediction
Nobody believed Larry Benedict's prediction in February 2020. The DOW plunged 3.5%, and he told CNBC, "It seems like there's much more to come." Within a month, the market plummeted 34%. Then, nobody believed Larry at the start of last year, either. He predicted that "all the indexes will be negative for the year," with the Nasdaq leading the way. Once again, he was spot-on.
Earnings Preview: DBV Technologies
Earnings Preview: DBV Technologies
DBV Technologies S.A. (DBVT)
See More Headlines
Receive DBVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DBV Technologies and its competitors with MarketBeat's FREE daily newsletter.

DBVT Company Calendar

Last Earnings
8/01/2021
Today
4/01/2023
Next Earnings (Estimated)
5/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:DBVT
Employees
92
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.38
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+218.0%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-96,270,000.00
Net Margins
-778.60%
Pretax Margin
-777.38%

Debt

Sales & Book Value

Annual Sales
$4.84 million
Book Value
$1.03 per share

Miscellaneous

Free Float
187,144,000
Market Cap
$318.18 million
Optionable
Optionable
Beta
1.23

Key Executives

  • Daniel Tassé
    Chief Executive Officer & Executive Director
  • Sébastien Robitaille
    Chief Financial Officer
  • Pharis Mohideen
    Chief Medical Officer
  • Pascal Wotling
    Chief Technical Operations & Quality Officer
  • Pascale Ehouarn
    Chief Engineering, Manufacturing & Supply Officer













DBVT Stock - Frequently Asked Questions

Should I buy or sell DBV Technologies stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for DBV Technologies in the last twelve months. There are currently 1 sell rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" DBVT shares.
View DBVT analyst ratings
or view top-rated stocks.

What is DBV Technologies' stock price forecast for 2023?

5 brokers have issued twelve-month target prices for DBV Technologies' stock. Their DBVT share price forecasts range from $1.50 to $10.00. On average, they predict the company's stock price to reach $5.38 in the next twelve months. This suggests a possible upside of 218.0% from the stock's current price.
View analysts price targets for DBVT
or view top-rated stocks among Wall Street analysts.

How have DBVT shares performed in 2023?

DBV Technologies' stock was trading at $1.53 at the start of the year. Since then, DBVT shares have increased by 10.5% and is now trading at $1.69.
View the best growth stocks for 2023 here
.

When is DBV Technologies' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 1st 2023.
View our DBVT earnings forecast
.

How were DBV Technologies' earnings last quarter?

DBV Technologies S.A. (NASDAQ:DBVT) posted its quarterly earnings data on Sunday, August, 1st. The company reported ($0.28) EPS for the quarter, beating analysts' consensus estimates of ($0.64) by $0.36. The firm had revenue of ($1.49) million for the quarter, compared to analyst estimates of $3.53 million. DBV Technologies had a negative trailing twelve-month return on equity of 52.54% and a negative net margin of 778.60%.

What other stocks do shareholders of DBV Technologies own?

Based on aggregate information from My MarketBeat watchlists, some companies that other DBV Technologies investors own include Aimmune Therapeutics (AIMT), OPKO Health (OPK), Bellicum Pharmaceuticals (BLCM), Axsome Therapeutics (AXSM), Gilead Sciences (GILD), Novavax (NVAX), AbbVie (ABBV), Pieris Pharmaceuticals (PIRS), Pfizer (PFE) and Sangamo Therapeutics (SGMO).

What is DBV Technologies' stock symbol?

DBV Technologies trades on the NASDAQ under the ticker symbol "DBVT."

How do I buy shares of DBV Technologies?

Shares of DBVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is DBV Technologies' stock price today?

One share of DBVT stock can currently be purchased for approximately $1.69.

How much money does DBV Technologies make?

DBV Technologies (NASDAQ:DBVT) has a market capitalization of $318.18 million and generates $4.84 million in revenue each year. The company earns $-96,270,000.00 in net income (profit) each year or ($0.65) on an earnings per share basis.

How can I contact DBV Technologies?

DBV Technologies' mailing address is 177-181 AVENUE PIERRE BROSSOLETTE, MONTROUGE I0, 92120. The official website for the company is www.dbv-technologies.com. The company can be reached via phone at (315) 542-7878, via email at sara.sherman@dbv-technologies.com, or via fax at 33-1-43-26-10-83.

This page (NASDAQ:DBVT) was last updated on 4/2/2023 by MarketBeat.com Staff